Evidence map›Paper›PMID 29765515›Full record

ArticleOncotarget2018

Cancer cell-selective, clathrin-mediated endocytosis of aptamer decorated nanoparticles.

Shira Engelberg, Julia Modrejewski, Johanna G Walter, Yoav D Livney, Yehuda G Assaraf

Abstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. The Atomically Precise Gold/Captopril Nanocluster AuACS applied materials & interfaces · 2022
    Article
  12. Article
  13. Article
  14. Foliate-Targeting Quantum Dots-International journal of molecular sciences · 2022
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shira EngelbergThe Laboratory of Food Physical Chemistry and Biopolymeric Delivery Systems, Department of Biotechnology and Food Engineering, Technion, Israel Institute of Technology, Haifa, Israel.
Julia ModrejewskiInstitute for Technical Chemistry, Leibniz University Hannover, Lower Saxony, Germany.
Johanna G WalterInstitute for Technical Chemistry, Leibniz University Hannover, Lower Saxony, Germany.
Yoav D LivneyThe Laboratory of Food Physical Chemistry and Biopolymeric Delivery Systems, Department of Biotechnology and Food Engineering, Technion, Israel Institute of Technology, Haifa, Israel.
Yehuda G AssarafThe Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the leading cause of cancer mortality worldwide, resulting in 88% deaths of all diagnosed patients. Hence, novel therapeutic modalities are urgently needed. Single-stranded oligonucleotide-based aptamers (APTs) are excellent ligands for tumor cell targeting. However, the molecular mechanisms underlying their internalization into living cells have been poorly studied. Towards the application of APTs for active drug targeting to cancer cells, we herein studied the mechanism underlying S15-APT internalization into human non-small cell lung cancer A549 cells. We thus delineated the mode of entry of a model nanomedical system based on quantum dots (QDs) decorated with S15-APTs as a selective targeting moiety for uptake by A549 cells. These APT-decorated QDs displayed selective binding to, and internalization by target A549 cells, but not by normal human bronchial epithelial BEAS2B, cervical carcinoma (HeLa) and colon adenocarcinoma CaCo-2 cells, hence demonstrating high specificity. Flow cytometric analysis revealed a remarkably low dissociation constant of S15-APTs-decorated QDs to A549 cells (K

Indexed as

aptamersclathrin-mediated endocytosislung cancermultidrug resistancetargeted delivery

Identifiers

PMID29765515
PMCPMC5940367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.